期刊文献+

IFN-λ4与HCV感染最新研究进展

Relationship between IFN-λ4 and HCV infection
原文传递
导出
摘要 干扰素(interferon,IFN)为体内主要的抗病毒细胞因子,新发现的III型干扰素IFN-λ4与丙型肝炎病毒(HCV)的自发清除或治疗无效密切相关。IFN-λ4只能存在于携带IFNL4-ΔG等位基因(rs368234815)个体,它是预测HCV清除的最佳宿主因素。IFN-λ4也通过IFN-λ受体复合物传递信号,并通过激活JAK-STAT途径诱导干扰素刺激基因(IFN-stimulatedgene,ISG)的表达。IFN-λ4能诱导抗病毒活性,却同时影响了HCV的有效清除。因此,解决IFN-λ4这种看似矛盾的功能问题,可能会对HCV感染和干扰素生物学的免疫反应产生重要的新见解。 Interferons (IFNs) are generally considered antiviral cytokines, yet the recently discovered IFN-λ4 is linked with the failure to clear hepatitis C virus (HCV) infection either spontaneously or in response to treatment. IFN-λ4 can be generated only by individuals who carry the 1FNL4-△G allele (rs368234815), which is the strongest known host factor for predicting clearance of HCV. IFN-λ4 signals through the IFN-λ, receptor complex and induces expression of IFN-stimulated genes via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. IFN-λ4 can induce antiviral activity yet impair ef- fective clearance of HCV. Resolving the paradoxical functions of IFN-λ4 may yield critical new insights into the immunologic response to HCV infection and IFN biology.
作者 李宁 侯炜
出处 《生命的化学》 CAS CSCD 2015年第4期491-494,共4页 Chemistry of Life
基金 国家自然科学基金项目(81271819)
关键词 Ⅲ型干扰素(IFN-λ) 丙型肝炎病毒 单核苷酸多态性(SNP) type Ⅲ IFN (IFN-λ) HCV SNP
  • 相关文献

参考文献21

  • 1Prokunina-Olsson L, Muchmore B, Tang W, et al. A vari- ant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 2013, 45:164-171.
  • 2Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clear- ance. Nature, 2009, 461:399-401.
  • 3Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon ct and ribavirin therapy. Nat Genet, 2009, 41:1100-1104.
  • 4Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interfer- on-α and ribavirin therapy for chronic hepatitis C. Nat Genet, 2009, 41:1105-1109.
  • 5Thomas DL, Thio CL, Martin MP, et al. Genetic varia- tion in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009, 461:798-801.
  • 6Rauch A, Kutalik Z, Descombes P, et al. Genetic varia- tion in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gas- troenterology, 2010, 138:1338-1345.
  • 7Thompson A J, Muir AJ, Sulkowski MS, et al. Interleu- kin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-lpatients. Gastroenterology, 2010, 139:120-129.
  • 8Pacanowski M, Amur S, Zineh I. New genetic discov- eries and treatment for hepatitis C. JAMA, 2012, 307: 1921-1922.
  • 9Honda M, Sakai A, Yamashita T, et al. Hepatic ISG ex- pression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology, 2010, 139:499-509.
  • 10Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B geno- type is associated with differential expression of intrahe- patic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology, 2010, 52:1888-1896.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部